MedTrace Logo

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

NCT00347919 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 189

Last updated 2016-02-25

Study results available
· View outcomes & findings →

Summary

This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the ErbB2 protein.

Conditions

  • Neoplasms, Breast

Interventions

DRUG

pazopanib (GW786034) 400 mg

400 mg administered orally once daily

DRUG

lapatinib (GW572016) 1500 mg

1500 mg administered orally once daily.

DRUG

lapatinib (GW572016) 1000 mg

1000 mg administered orally once daily

DRUG

pazopanib (GW786034) 800 mg

800 mg administered orally once daily

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-08-31
Completion
2015-03-31

Countries

  • United States
  • Canada
  • France
  • Hungary
  • India
  • Israel
  • Malaysia
  • Mexico
  • Pakistan
  • Peru
  • Poland
  • Russia
  • Singapore
  • South Korea
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00347919 on ClinicalTrials.gov